| Prev Close | 62.98 |
| Day Low/High | 63.07 / 64.81 |
| 52 Wk Low/High | 62.66 / 100.23 |
| Avg Volume | 9.97M |
AbbVie Inc. (ABBV)
64.43
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 1.48B |
| Market Cap | 93.11B |
| EPS | 3.70 |
| P/E Ratio | 22.41 |
| Div & Yield | 4.28 (6.57%) |
Latest News
Draghi's End Game and a 3-Way Battle Shapes Up in the Cloud: Market Recon
Plus, Intel results crush expectations and Starbucks solidifies its comeback.
One Prescription for Uncertain Market? Gilead Sciences
Use buy-write orders as a conservative way to invest in GILD in these uneasy times.
Buyout Speculation Picks Up in Biotech
Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.
AbbVie Insiders Buying Shares
Stocks see a nice surge on the open on optimism around trade talks resuming between the U.S. and China, although negotiations will be ongoing for many months and no permanent resolution seems on the horizon. The U.S. PMI Manufacturing Index also cam...
Now at the Plate, Your Pinch Hitter, Bret Jensen!
It is good to be sitting in for Doug Kass here on The Daily Diary as we open trading in the second half of 2019. June ended on an up note as all the major indices drifted up last week to close out the month and quarter. The market did an admirable j...
My 3 Predictions for the Second Half of 2019
Watch the Russell 2000, housing activity, and mergers and acquisitions.
AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech
The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.
Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere
The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.
I Believe AbbVie and Allergan Need Each Other
With no other bidder expected to emerge, this is a high risk arbitrage play.
Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015
PFE was ready to pay $160 billion until U.S. regulators blocked the deal.
AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
AbbVie Is Likely to Decline as Investors Digest Its Takeover Announcement
Let's look closer at the charts and indicators of ABBV.
AbbVie Fizzles, Gold, Bitcoin and (Some) Biotech Sizzles
AbbVie is dropping on Allergan deal announcement, momentum is weak outside certain pockets.
A Six-Pack of Biotech Best Bets
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
Earnings, Earnings and More Earnings, Facebook Results: Market Recon
As we have seen so far, in terms of market reaction, there is great reward at the point of sale in beating expectations.
Are These Stocks the Best of the Best?
Screening Goldman Sachs' list of the top 20 stocks to see which ones are the best technical opportunities.
5 Attractive Ways to Invest in Oncology
Experts offer their top stock ideas in oncology detection and treatment.
Why Risk-On Is In Vogue, Updating Zuora: Market Recon
China's central bank announced a bill swap mechanism late Thursday aimed at slowing down the nation's economic slowdown.
Takeda Pharmaceutical CEO Talks Big Pharma Trends
One of pharma's biggest CEO's talks M&A action on the exchange.
Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun
And it is happening not a moment too soon.
3 Key Bear Market Rules, 5 Bargain Buys and a Monthly Dividend Portfolio
Dow Theory presents tips for surviving a bear market, some top year-end stock bargains and a simple strategy for monthly income.
Nibble on This Bearish Strategy in Shake Shack: Market Recon
SHAK beat expectations for both EPS and revenue, but same-store sales decreased. Here is how I would play it.
Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken
Once the safest stocks in the book, the big-cap drug companies are now toxic.
